LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH ORION-8: Inclisiran shows efficacy and safety beyond six years Phase 3 data show benefits of alirocumab in children with HeFH REMAIN-1: Recaticimab significantly reduces LDL-C even with infrequent dosing Phase 3 programme for MK-0616 gets underway MK-0616 – How near is an oral PCSK9i?

NOW AVAILABLE: Download the first of the PCSK9 Forum expert slide resources: FOURIER and ODYSSEY OUTCOMES

Posted on 10 April 2019 |

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters